Brahm Segal

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. Singel K, Grzankowski K, Khan A, Grimm M, D Auria A, Morrell K, et al. Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. Br J Cancer. 2019;120:207-217 pubmed publisher
    ..Mitochondrial and other DAMPs in ascites may activate neutrophil and platelet responses that facilitate metastasis and obstruct anti-tumour immunity. These pathways are potential prognostic markers and therapeutic targets. ..
  2. request reprint
    Segal B, Kwon Chung J, Walsh T, Klein B, Battiwalla M, Almyroudis N, et al. Immunotherapy for fungal infections. Clin Infect Dis. 2006;42:507-15 pubmed
    ..g., vaccines). Immunotherapy must be tailored to specific immunocompromised states. Challenges exist in bringing promising immunotherapies from the laboratory to clinical trials. ..
  3. Segal B, Herbrecht R, Stevens D, Ostrosky Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-83 pubmed publisher
    ..We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge. ..
  4. Segal B, Romani L, Puccetti P. Chronic granulomatous disease. Cell Mol Life Sci. 2009;66:553-8 pubmed publisher
    ..This model is based on studies in mice and requires correlation in humans. ..
  5. Segal B, Romani L. Invasive aspergillosis in chronic granulomatous disease. Med Mycol. 2009;47 Suppl 1:S282-90 pubmed publisher
  6. request reprint
    Segal B, Steinbach W. Combination antifungals: an update. Expert Rev Anti Infect Ther. 2007;5:883-92 pubmed
    ..We review data from in vitro and animal model studies as well as insights from clinical trials to discuss current thoughts and highlight the gaps in our knowledge surrounding combination antifungal therapy. ..
  7. Kolomeyevskaya N, Eng K, Khan A, Grzankowski K, Singel K, Moysich K, et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015;138:352-7 pubmed publisher
    ..This study involved a small sample of patients and was an exploratory analysis; therefore, findings require validation in a larger independent cohort. ..
  8. Singel K, Segal B. NOX2-dependent regulation of inflammation. Clin Sci (Lond). 2016;130:479-90 pubmed publisher
  9. request reprint
    Segal B, Holland S. Primary phagocytic disorders of childhood. Pediatr Clin North Am. 2000;47:1311-38 pubmed
    ..Prophylactic antibiotics, BMT, and the use of exogenous cytokines, such as IFN-gamma and G-CSF, are appropriate for specific phagocytic disorders. Gene therapy is a promising strategy for several of the phagocytic disorders...

More Information

Publications13

  1. request reprint
    Segal B. Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. Oncologist. 2007;12 Suppl 2:7-13 pubmed
    ..Macrophages are therefore a target for immune augmentation strategies that include administration of cytokines, colony-stimulating factors, and pathogen recognition receptor ligands...
  2. Segal B, Han W, Bushey J, Joo M, Bhatti Z, Feminella J, et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS ONE. 2010;5:e9631 pubmed publisher
    ..These studies support a model in which NADPH oxidase-dependent, redox-mediated signaling is critical for termination of lung inflammation and suggest new potential therapeutic targets for CGD. ..
  3. Mayor P, Eng K, Singel K, Abrams S, Odunsi K, Moysich K, et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2018;141:1028-1035 pubmed publisher
    ..These data point to a restricted role of the immune system in protecting from specific cancers. ..
  4. Szender J, Emmons T, Belliotti S, Dickson D, Khan A, Morrell K, et al. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol. 2017;146:491-497 pubmed publisher
    ..If these findings are confirmed in independent studies, consideration should be made to add the presence of large volume ascites at diagnosis to the staging criteria for ovarian cancer. ..